Pfizer's Viagra losing market share in Russia

1 November 2022

The share of US pharma giant Pfizer’s (NYSE: PFE) erectile dysfunction drug Viagra (sildenafil) in the Russian market is steadily declining, due to the ever-growing competition from local generics and serious interruptions with supplies of the drug from Europe.

According to the Russian pharma analytics agency, the DSM Group, over the past 40 weeks, retail sales of the drug – once of the most popular in Russia - have declined by 5% in value terms and by 22% in volume year-on-year basis.

As representatives of SoyuzPharma, the Russian Association of Pharmacies, said in an interview with the Russian Expert business paper, the supplies of Viagra to Russia did not stop completely, but have significantly declined.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK